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@unimi.itAbstractAdipogenesis is a complex process modulated by several factors, including cAMP signaling.
The main cAMP target is protein kinase A (PKA), a tetrameric enzyme with four regulatory
subunits showing tissue-specific expression and function: PRKAR2B is the main regulatory
subunit in adipose tissue in mice and in adult humans. This study aimed to evaluate the
expression of PKA regulatory subunits in human adipose tissue during fetal development
and to investigate their role in the differentiation of 3T3-L1 and primary human
preadipocytes. The expression of PKA regulatory subunits was evaluated in fetal adipose
tissue (immunohistochemistry) and in cultured 3T3-L1 and primary human preadipocytes
(western blot analysis). Cultured cells were transiently transfected with siRNA against
PRKAR2B and induced to differentiate. Differentiation was evaluated by intracellular
triglyceride staining (Oil Red O) and expression of molecular markers of adipocyte
differentiation. In this study, we found that PRKAR2B is the main regulatory subunit in
human adipose tissue during fetal development, from 12 weeks of gestation to the end of
gestation, as well as in 3T3-L1 and primary human preadipocytes. The expression of PRKAR2B
increases progressively during in vitro differentiation. The silencing of PRKAR2B abolishes
the increase in the expression of peroxisome proliferator-activated receptor gamma (PPARg
(PPARG)), fatty acid synthase, aP2 (FABP4), and lipoprotein lipase, as well as intracellular
triglyceride accumulation, resulting in impaired adipocyte differentiation in both mouse and
human cell systems. In conclusion, PRKAR2B is the key PKA regulatory subunit involved in
mouse and human adipose tissue development. The physiological increase in the expression
of PRKAR2B is an essential event in adipogenesis in both mice and humans, and it might
represent a possible target for future strategies for obesity treatment.Key Words
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" cAMP
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2–12 2 :197IntroductionWhite adipose tissue (WAT) is mainly involved in energy
storage and mobilization in the form of triglycerides,
although a paracrine and endocrine function of white
adipocytes has also been recognized. Excess of WAT results
from an increase in both adipocyte size and number, and it
is associated with obesity and related metabolic disorders.
Adipogenesis is a complex, not completely clarified
process characterized by a cascade of gene activation
processes tightly controlled by a myriad of different factors
(1, 2), which have been only partially elucidated.
cAMP acts as an intracellular second messenger in
the regulation of a number of different cellular processes,
such as cell growth and differentiation. It is known that
cAMP signaling also affects adipogenesis, through
different and partially unexplored mechanisms. Indeed,
3-isobutyl-1-methylxanthine (IBMX), one of the inducers
of adipogenesis, acts through the increase in intracellular
cAMP levels. The activation of cAMP-responsive element-
binding protein (CREB) induces the expression of several
transcription factors that promote adipogenesis, mainly
CCAAT/enhancer-binding proteins (C/EBPs) and per-
oxisome proliferator-activated receptor gamma (PPARg
(PPARG)) (3, 4, 5, 6). In addition, the increase in
intracellular cAMP levels leads to the production of a
putative endogenous PPARg ligand (7). Although a role
for exchange protein directly activated by cAMP (EPAC
(RAPGEF3)) in cAMP-mediated adipocyte differentiation
has been suggested (8), evidence indicates that the
activation of CREB is mainly modulated by cAMP-
dependent protein kinase A (PKA) (9).
PKA is a tetrameric enzyme composed of two catalytic
and two regulatory subunits. There are four regulatory
subunits (R1A, R1B, R2A, and R2B) differently expressed in
mammalian tissues, affecting cAMP-dependent functions
(10). In adipose tissue, the major holoenzyme assembled
under normal conditions contains the R2B regulatory
subunit, even though both PRKAR2B and PRKAR1A are
expressed in fat cells (11, 12). Targeted disruption of the
Prkar2b gene in mice leads to stable alterations in energy
storage and utilization, resulting in a lean phenotype (13).
It has been reported that human adipose tissue exhibits
important BMI-related differences in the expression and
activity of PRKAR2B that might contribute to the variability
of cAMP-stimulated lipolysis in obese and nonobese
subjects (12). However, data on the expression and
function of the different PKA regulatory subunits during
adipose tissue differentiation are few and contradictory
(14, 15). Moreover, these studies have been carried out inhttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0049
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Published by Bioscientifica Ltdmurine cell line models, mainly 3T3-L1 preadipocytes,
while studies in human models of adipocyte differentiation
are still scarce.
In this study, we evaluated the expression of PKA
regulatory subunits in human adipose tissue during fetal
development as well as their role in the differentiation
process of two in vitro cell models of adipogenesis, i.e.,
3T3-L1 and primary human preadipocytes. Our data
showed that the physiological increase in the expression
of PRKAR2B is an essential event in adipogenesis in both
mice and humans.Materials and methods
Fetal tissues
Tissues from fetuses of gestational ages 12, 14, 20, 25, and
36 weeks were collected, as described previously (16).
Briefly, fetuses of gestational ages 12, 14, 20, and 25 weeks
were collected after legal voluntary termination of
pregnancy for maternal psychiatric disorders, according
to the Italian legislation that allows termination of
pregnancy for medical reasons up to 25 weeks of gestation.
Fetal death at 36 weeks was due to abruptio placentae for
unexplained reasons. In all cases, informed consent of the
mother was obtained before procurement of the tissues, in
accordance with the guidelines outlined by the San Paolo
Institute Ethics Committee. Samples were fixed in 10%
buffered formalin and paraffin-embedded for immuno-
histochemistry (IHC). At least two samples of each fetal
tissue from two different fetuses at each given trimester of
gestation were analyzed in three separate experiments.Immunohistochemistry
Sections from paraffin-embedded fetal tissues were pro-
cessed for IHC, as reported previously (17). A polyclonal
antibody against human delta-like protein 1 (DLK1), also
known as preadipocyte factor 1 (Pref1) (Abcam, Cambridge,
UK), was used to identify fibroblast-like preadipocytes not
identifiable by morphological evaluation. Specific MABs
against PRKAR1A, PRKAR2A, and PRKAR2B were used under
the conditions specified by the manufacturer (BD Trans-
duction Laboratories, Lexington, UK). Antigen–antibody
detection was carried out using the DAKO ChemMate En
Vision detection kit (DAKO A/S, Glostrup, Denmark)
according to the manufacturer’s instructions. Sections
were stained with 3,30-diaminobenzidine substrate andThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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3–12 2 :198counterstained with Mayer’s hematoxylin, and slides were
prepared for light microscopy examination, as described
previously (17). Negative controls were obtained by
occulting the primary antibody or by using an unrelated
mouse MAB.Cell preparation, culture, and differentiation
Murine 3T3-L1 preadipocytes (kindly provided by J A M
Maier, Milan, Italy) were grown until confluence at 37 8C
and in 5% CO2 in DMEM supplemented with 10% calf
serum and 100 units/ml penicillin and 100 mg/ml strepto-
mycin. Two days after confluence, differentiation was
induced (day 0) by changing the growth medium to
differentiation medium, containing DMEM with 10% fetal
bovine serum (FBS), 0.5 mmol/l IBMX, 1 mmol/l dexametha-
sone, and 10 mg/ml insulin; after 48 h, the cells were
maintained in DMEM with 10% FBS and the medium was
changed every 2 days. The cells differentiated within 8 days.
Human subcutaneous adipose tissue samples from
normal (BMI between 18.5 and 25 kg/m2) healthy subjects
were collected from the surgical incision site during
abdominal surgical procedures for benign disease (elective
cholecystectomy). The study was approved by the local
ethics committee, and all the subjects gave informed
consent before participation, according to the Declaration
of Helsinki. The samples were digested with collagenase
type 2 (Sigma–Aldrich), and preadipocytes were isolated as
described previously (12), on the basis of cell dimension
and density.
Primary human preadipocytes were cultured until
they reached the total confluence stage in complete Preadi-
pocyte Growth Medium (PromoCell GmbH, Heidelberg,
Germany), a low-serum medium optimized for primary
human cells containing DMEM F12 with 5% fetal calf
serum (FCS), 0.4% endothelial cell growth supplement,
10 ng/ml epidermal growth factor (recombinant human),
and 1 mg/ml hydrocortisone. After confluence, the growth
medium was replaced with Preadipocyte Differentiation
Medium (Promocell GmbH), a serum-free medium
containing DMEM F12 with 8 mg/ml D-biotin, 0.5 mg/ml
insulin (recombinant human), 400 ng/ml dexametha-
sone, 44 mg/ml IBMX, 9 ng/ml L-thyroxine, and 3 mg/ml
ciglitazone. The cells were maintained in Preadipocyte
Differentiation Medium for 72 h to induce the differen-
tiation of preadipocytes into mature adipocytes. Then, the
medium was changed to Adipocyte Nutrition Medium
(Promocell GmbH), containing DMEM F12 with 3% FCS,
8 mg/ml D-biotin, 0.5 mg/ml insulin (recombinant human),
and 400 ng/ml dexamethasone. The cells were fed everyhttp://www.endocrineconnections.org
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Published by Bioscientifica Ltd2–3 days with fresh Adipocyte Nutrition Medium to
complete the differentiation process. The cells differen-
tiated after 12–14 days.Oil Red O staining
The cells were washed three times with PBS, fixed in 10%
formalin in PBS for 10 min at room temperature, washed
once again with PBS, and then stained with 60% filtered
Oil Red O stock solution (0.35 g Oil Red O (Sigma–Aldrich)
in 100 ml isopropanol) for 20 min, washed four times with
water, and then analyzed under a microscope. The cells
were photographed using a phase-contrast microscope
(Nikon Eclipse Ti inverted microscope; objective: Nikon
CFI Plan Achromat DL 20!).Synthesis and transfection of siRNA
siRNAs against mouse and human PRKAR2B genes (R2B
siRNA) were obtained from Dharmacon (Chicago, IL, USA).
Subconfluent 3T3-L1 cells were transfected with
double-stranded RNA using the siPORT NeoFX transfec-
tion reagent (Ambion, Austin, TX, USA), according to the
manufacturer’s instructions. Both siRNA (10 nM) and
siPORT NeoFX were diluted in Opti-MEM I Reduced-
Serum Medium (Invitrogen). The cells were exposed to
double-stranded RNA and transfection reagent for 24 h.
Then, the culture medium was replaced with fresh normal
growth medium.
Primary human preadipocytes were transfected with
double-stranded RNA using the HiPerFect Transfection
Reagent (Qiagen), according to the manufacturer’s instruc-
tions. Similar to the procedure followed for 3T3-L1 cells,
siRNA was diluted in Opti-MEM I Reduced-Serum Medium.
The cells were exposed to double-stranded RNA (10 nM)
and transfection reagent for 72 h. Then, the culture
medium was replaced with fresh normal growth medium.
In order to identify nonspecific effects, a negative
control siRNA, a nontargeting sequence that has no
significant homology to the sequence of human, mouse,
or rat transcripts, was used in each experiment. siRNA
against GAPDH was used as an internal positive control.
Western blot analysis was carried out in each experiment
to determine the expression levels of PRKAR2B in the
silenced cells.
Preliminary experiments to determine the optimal
concentration of siRNAs and the kinetics of PRKAR2B
silencing were carried out. The efficiency of silencing was
about 60% in both the cell models. Silencing was effective
after 48 and 72 h in 3T3-L1 and primary humanThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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4–12 2 :199preadipocytes respectively, and it lasted until 10–11 days
in both the cell models.Western blot analysis and mitotic clonal
expansion evaluation
Western blot analysis was carried out, as described
previously (17), on total protein extracts from 3T3-L1
cells and primary human preadipocytes. Antibodies
against PRKAR1A, PRKAR2A, PRKAR2B, and catalytic
subunits were obtained from BD (BD Transduction
Laboratories). Polyclonal antibodies against both PPARg
1–2 and lipoprotein lipase (LPL) were obtained from
Santa Cruz Biotechnology. Antibodies against aP2 (fatty
acid-binding protein 4, FABP4) and fatty acid synthase
(FAS) were obtained from GeneTex (Irvine, CA, USA). MAB
against GAPDH was obtained from Ambion.
Chemiluminescence was detected using the Chemi-
Doc-IT Imaging System (UVP, Upland, CA, USA) and
analyzed using the image analysis program NIH ImageJ.
All the experiments were repeated at least three times
with comparable results. The experiments on primary cell
cultures were carried out on at least three different samples
from different subjects.Pref1/PRKAR2B
36 weeks
human
fetus
PRKAR2BPref1A
14 weeks
human
fetus
50 µm 50 µm
50 µm50 µm
300 µm
300 µm
Figure 1
(A) Immunohistochemistry for Pref1 and PRKAR2B carried out in human
perirenal adipose tissue of 14-week and 36-week-old fetuses, as
representative examples. Immunostaining for Pref1 was carried out to
identify fibroblast-like preadipocytes. Positive immunostaining for Pref1
was observed in the adipose tissue of a 14-week-old fetus, positive
immunostaining was also observed for PRKAR2B. Double immunostaining
for Pref1 (red) and PRKAR2B (brown) was observed in the preadipocytes of
the 14-week-old fetus. The adipose tissue of the 36-week-old fetus was
mainly composed of mature adipocytes (Pref1K). Positive immuno-
reactivity for PRKAR2B was observed in mature adipocytes of the
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cells were transfected with R2B or negative control siRNA
for 72 h and then induced or not induced to differentiate.
After 48 h, the cells were trypsinized, and the number
of cells was determined using a hemocytometer.Statistical analysis
The results are expressed as meansGS.D. The unpaired
two-tailed Student’s t-test was used to determine the
significance of differences between two series of data.
P!0.05 was classified as statistically significant.Results
PRKAR2B expression in human adipose tissue during
fetal development
In order to investigate the expression of PKA regulatory
subunits in human adipose tissue during fetal develop-
ment, IHC was carried out on tissue sections of adipose
tissue obtained from fetuses of different gestational ages.
To identify preadipocytes within the mesenchymal tissue
surrounding organs in fetuses of early gestational ages,B
20 weeks
human
fetus
25 weeks
human
fetus
PRKAR2B PRKAR1A
Positive
control
25 µm
25 µm
25 µm
25 µm
36-week-old fetus. Magnification!20. Panels on the right, magnification
!120. (B) Immunostaining for PRKAR2B and PRKAR1A carried out in
human retroperitoneal adipose tissue of 20-week-old (adrenal) and
25-week-old (bladder) fetuses, as representative examples. Visceral adipose
tissue from fetuses of gestational ages 20 and 25 weeks was composed of
both preadipocytes and mature adipocytes (see inset), with intense
immunopositivity for PRKAR2B and low immunopositivity for PRKAR1A
protein. Magnification !10, inset !40. Intense immunopositivity for
PRKAR1A in human kidney sample is shown as a positive control.
Magnification !10.
This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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Figure 2
Representative western blot analysis of the expression of PRKAR2B and
PRKAR1A proteins in 3T3-L1 cells carried out before (D0) and after 2 and
5 days of differentiation (D2 and D5) respectively. PRKAR2B was the most
expressed PKA regulatory subunit at each stage of differentiation. The
expression of PRKAR2B and PRKAR1A increased progressively until day 5
(D5) and then it remained constant. Data were normalized through GAPDH
antibody hybridization. Chemiluminescence was detected using the
ChemiDoc-IT Imaging System and analyzed using ImageJ. The values are
expressed as relative increase when compared with the basal value,
arbitrarily fixed as 1. All the experiments were repeated at least three times
with similar results. Data are presented as meansGS.D. *P!0.01 vs D0;
§P!0.05 vs D2.
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Figure 3
Representative western blot analysis of the expression of PRKAR2B
and PRKAR1A proteins in primary human preadipocytes carried out
before (D0) and after 5 and 8 days of differentiation (D5 and D8)
respectively. PRKAR2B was the most expressed PRKA regulatory
subunit at each stage of differentiation. The expression of PRKAR2B
and PRKAR1A increased progressively until day 8 (D8) and then it
remained constant. Data were normalized through GAPDH antibody
hybridization. After digital acquisition, chemiluminescence was
measured using ImageJ, and the values are expressed as relative
increase when compared with the basal value, arbitrarily fixed as 1.
At least three experiments with primary cultures from samples of
different subjects were repeated with similar results. Data are
represented as meansGS.D. #P!0.001 vs D0 and D5 respectively;
*P!0.01 vs D0; §P!0.05 vs D5.
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5–12 2 :200IHC with an antibody against Pref1, a marker of early
preadipocytes, was carried out.
IHC indicated that PRKAR2B was the main regulatory
subunit in human adipose tissue during fetal develop-
ment, starting from 12 weeks of gestation. In particular,
IHC revealed a weak immunopositivity for PRKAR2B,
which co-localized with Pref1, in fibroblast-like preadipo-
cytes in periorbital and retroperitoneal mesenchymal
tissue obtained from fetuses of gestational ages 12 and
14 weeks and the absence of PRKAR1A.
Visceral adipose tissue almost entirely composed of
mature adipocytes, as indicated by the negative staining
for Pref1, as well as a subcutaneous adipose layer, was
present in the tissue sections of 36-week-old fetuses. In
these sections, the expression of PRKAR2B was high
(Fig. 1A), whereas that of PRKAR1A was nearly absent.http://www.endocrineconnections.org
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Published by Bioscientifica LtdIn 20- and 25-week-old fetuses, visceral adipose tissue
exhibited intermediate features when compared with
the tissue present during the first and the last few weeks
of gestation, being composed of both preadipocytes
(Pref1C) and morphologically distinct mature adipocytes
(Pref1K). In the sections of retroperitoneal adipose tissue,
the expression of PRKAR2B was high, whereas that of
PRKAR1A was low (Fig. 1B), mimicking what was observed
in adult human adipose tissue (12).This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
E
n
d
o
cr
in
e
C
o
n
n
e
ct
io
n
s
Research E Peverelli et al. Role of PRKAR2B in
adipogenesis
6–12 2 :201PRKAR2B expression increases during adipogenesis in
both murine and human cell models
PRKAR2B was the most expressed regulatory subunit in
3T3-L1 cells before and during in vitro differentiation. The
expression of PRKAR2B was low in 3T3-L1 cells before
differentiation, and it increased progressively from day 0
to day 5 of differentiation and then remained constant
(Fig. 2). PRKAR1A was nearly absent before differentiation,A
B
D8 basal
3T3-L1
Human
preadipocytes
C
Human
preadipocytes
PKAR2B
GAPDH
D
Bas C- R2B siR
3T3-L1, D8
D8 n
Figure 4
Representative images of intracellular lipid accumulation after
differentiation of 3T3-L1 cells and primary human preadipocytes. siRNA
against PRKAR2B inhibited 3T3-L1 and human preadipocyte differentiation.
(A) 3T3-L1 cells. Oil Red O staining of nontransfected cells, cells transfected
with the negative control siRNA, and cells transfected with siRNA against
PRKAR2B respectively after 8 days of induction of differentiation. (B) Human
preadipocytes. Phase-contrast images of nontransfected cells, cells trans-
fected with the negative control siRNA, and cells transfected with siRNA
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Published by Bioscientifica Ltdand its expression increased progressively during the first
few days of differentiation in 3T3-L1 cells, though
remaining at lower levels when compared with that of
PRKAR2B (Fig. 2).
PRKAR2B was also the most expressed regulatory
subunit in primary human preadipocytes before and
during differentiation, a pattern similar to that observed
in 3T3-L1 cells. It is worth noting that the differentiationD8 R2B siRNA
NA Bas C- R2B siRNA
Human preadipocytes, D8
53 kDa
36 kDa
egative control
against PRKAR2B respectively after 8 days of induction of differentiation.
(C) Human preadipocytes. Oil Red O staining of nontransfected cells, cells
transfected with the negative control siRNA, and cells transfected with
siRNA against PRKAR2B respectively after 8 days of induction of differen-
tiation. The cells were photographed using a phase-contrast microscope.
Magnification!20, inset: close-up view. (D) Immunoblots showing the
expression of PRKAR2B in control cells and silenced cells on D8 of
differentiation in both 3T3-L1 and human preadipocytes.
This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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7–12 2 :202process was slower in human preadipocytes than in
3T3-L1 cells. In fact, the expression of PRKAR2B, which
was low in undifferentiated preadipocytes, increased
progressively after the start of differentiation and reached
its highest levels after 8 days (Fig. 3) and remained
constant thereafter. The expression of PRKAR1A was very
low in primary human adipocytes before differentiation,
and a slight increase was observed after 8 days of
differentiation (Fig. 3).PRKAR2B
GAPDH
PRKAR2A
Prkar2b
siRNA
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control
53 kDa
51 kDa
40 kDaPKA C
36 kDa
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Figure 5
Effects of R2B silencing on the other subunits of PKA in 3T3-L1 cells.
The cells were transfected for 72 h with negative control or R2b siRNA.
Immunoblots with specific antibodies against PRKAR2B, PRKAR1A,
PRKAR2A, and catalytic (C) subunits were obtained. Experiments were
repeated three times with similar results, and a representative western blot
is shown. Values are expressed as relative increase when compared with the
basal value, arbitrarily fixed as 1. Data are presented as meansGS.D.
*P!0.01 vs basal value.PRKAR2B is a positive regulator of adipogenesis
Since PRKAR2B was the most expressed regulatory subunit
in our cell models and its expression increased progressively
during adipocyte differentiation, we decided to investigate
the effects of its silencing on adipogenesis. For this purpose,
murine 3T3-L1 cells and primary human preadipocytes
were transfected with siRNA againstPRKAR2B to transiently
reduce the expression of PRKAR2B during differentiation
and thereafter induced by standard protocols.
The progression of the physiological adipocyte differ-
entiation process is characterized by a change in cell
morphology from fibroblast-like preadipocytes to round-
shaped cells. The increase in intracellular lipid accumu-
lation, mainly as triglyceride droplets, can be visualized
by Oil Red O staining. Using this approach, although
lipid accumulation was found to be slower in human
preadipocytes than in 3T3-L1 cells, triglyceride droplets
were well visualized in both the cell types after 8 days,
a time lag covered by the duration of transfection and
silencing (Fig. 4D).
The silencing of PRKAR2B resulted in reduced tri-
glyceride accumulation in both 3T3-L1 cells (Fig. 4A)
and primary human preadipocytes (Fig. 4B and C),
when compared with nonsilenced or negative control
siRNA-transfected cells. As the increase in intracellular
triglyceride accumulation observed after the application
of adipogenic stimuli was similar in nontransfected cells
and cells transfected with the negative control siRNA,
a nonspecific effect of transfection on the inhibition of
adipocyte differentiation was ruled out in both the cell
systems (Fig. 4A, B, and C).
To investigate the effects of PRKAR2B ablation from
the PKA complex, using western blot analysis, we
evaluated the expression of other PKA subunits after 72 h
of PRKAR2B silencing in 3T3-L1 and human preadipocytes
(Fig. 5 and data not shown). Our data showed that in
both the cell models, the expression of the PRKAR1A
subunit was significantly increased after R2B silencing,
suggesting a compensatory increase, as observed in otherhttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0049
 2013 The authors
Published by Bioscientifica Ltdcell systems (13). By contrast, no differences in the
expression of PRKAR2A, which was very low, and catalytic
subunits were observed.
The exposure of 3T3-L1 cells to adipogenic stimuli
initiates MCE, an event that precedes the expression of
genes involved in adipocyte differentiation. However,
it is still unknown whether this step is a prerequisite for
differentiation. To determine whether the silencing ofThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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8–12 2 :203PRKAR2B might also have effects on the MCE process, we
transfected cells with R2B siRNA or negative control
siRNA, and we determined the number of cells 48 h after
the induction of differentiation. Our results indicated an
increase of about twofold in the number of cells induced
to differentiate with respect to uninduced cells at the same
time point. No differences were found between the control
cells or R2B-silenced cells.PRKAR2B silencing abolished the increase in adipocyte
differentiation molecular markers
During the first few days of differentiation, both 3T3-L1
and primary human preadipocytes transfected with the
negative control siRNA exhibited a progressive increase
in the expression of PPARg, with the highest expressionD0D2D5 D0D2D5D7
56
53
36
siRNA r2b Control
PPARγ
PRKAR2B
GAPDH
FABP4
PRKAR2B
GAPDH
siRNA r2bControl
D0 D2 D5
15 k
53 k
36 k
D0 D2 D5
FAS
PRKAR2B
GAPDH
siRNA r2bControl
D0 D2 D5
273
53 k
36 
D0 D2 D5
Figure 6
Representative western blot analysis of the expression of PPARg, FABP4,
and FAS in 3T3-L1 cells carried out before (D0) and after 2 and 5 days of
differentiation (D2 and D5) respectively. In control cells transfected with
the negative control siRNA, the expression of PPARg, FABP4, and FAS
increased progressively during the first few days of normal 3T3-L1 cell
differentiation. In the Pkar2b-silenced cells, the expression of PPARg,
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Published by Bioscientifica Ltdoccurring on days 5 and 8 respectively and remaining
constant thereafter (Figs 6 and 7, control cells).
The silencing of Prkar2b abolished the increase in the
expression of PRKAR2B during differentiation. Most
importantly, under these experimental conditions, the
expression of PPARg did not increase in 3T3-L1 and
primary human preadipocytes, when compared with
control cells.
Accordingly, the silencing of PRKAR2B in 3T3-L1
cells also completely abolished the increase in the
expression of FABP4 and FAS during the induction of
differentiation (Fig. 6).
Moreover, the expression of LPL, a marker of complete
adipocyte differentiation, was also impaired in silenced
primary human preadipocytes, when compared with
control cells (Fig. 8).0
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Figure 7
Representative western blot analysis of the expression of PPARg in primary
human preadipocytes carried out before (D0) and after 5 and 8 days of
differentiation (D5 and D8) respectively. PPARg antibody detected only an
immunoreactive band corresponding to PPARg2 isoform (56 kDa). The
expression of PPARg increased progressively during adipocyte differen-
tiation (negative control cells). The silencing of PRKAR2B was effective
before and during the differentiation of primary human preadipocytes.
The expression of PPARg did not increase after the administration of
adipogenic stimuli in human preadipocytes transfected with siRNA against
PRKAR2B. Data were normalized through GAPDH antibody hybridization.
Values are expressed as relative increase when compared with the basal
value, arbitrarily fixed as 1. All the experiments were repeated at least
three times with similar results. Data are presented as meansGS.D. §P!0.05
vs D0 and D5 respectively; *P!0.01 vs D0.
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9–12 2 :204Discussion
In this study, we evaluated the role of PKA regulatory
subunits in adipogenesis, as an extension of previous
investigations carried out in our laboratory (12). Our study
first demonstrated that PRKAR2B is highly expressed in
human fetal tissues and is required for adipocyte differen-
tiation in vitro.
In line with previous reports on mice and adult
humans (11, 12, 13), the present study provides data
indicating that PRKAR2B is the key PKA regulatory subunit
in human adipose tissue during fetal development. Little
is known about the formation of WAT during human
development, and most of the data concerning adipocyte
differentiation have been obtained from in vitro studies
(1, 2). Interestingly, while in rodents WAT cannot be
macroscopically detected during embryogenesis andhttp://www.endocrineconnections.org
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Published by Bioscientifica Ltddevelops mainly after birth, in human fetuses the
formation of WAT starts well before birth (18).
In accordance with the study of Poissonnet et al. (19), we
detected preadipocytes in periorbital tissue at 12 weeks of
gestation using the preadipocyte marker Pref1, an
epidermal growth factor-like domain-containing trans-
membrane protein expressed by adipocyte precursors and
known to inhibit adipocyte differentiation (20, 21). Our
data indicated that during the early phases of fetal
development PRKAR2B is the only PKA regulatory subunit
expressed in human adipose tissue where it co-localizes
with Pref1. In the subsequent phases and until the end of
gestation, when fetal adipose tissue has nearly acquired
the features of adult adipose tissue, the expression of
PRKAR2B is high, while Pref1 disappears, due to the
decrease in the amount of preadipocyte precursors.This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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Figure 8
Representative western blot analysis of the expression of LPL in primary
human preadipocytes carried out before (D0) and after 5 and 8 days of
differentiation (D5 and D8) respectively. The expression of LPL increased
during the differentiation of human adipocytes (negative control cells).
The expression of LPL did not increase after the administration of
adipogenic stimuli in human preadipocytes transfected with siRNA
for PRKAR2B. Data were normalized through GAPDH antibody hybrid-
ization. The values are expressed as relative increase when compared with
the basal value, arbitrarily fixed as 1. All the experiments were repeated at
least three times with similar results. Data are presented as meansGS.D.
*P! 0.01 vs D0; §P!0.05 vs D5.
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10–12 2 :205It is well established that there are distinct and cell-
specific roles for the different PKA isoenzymes in the
regulation of growth control and differentiation (7, 10, 17,
22, 23, 24, 25). In particular, studies in Prkar2b knockout
mice have shown that these animals remain remarkably
lean due to increased metabolic activity (13), probably
due to compensatory increase in the expression of
PRKAR1A regulatory subunit. However, PRKAR2B mRNA
levels have been found to be significantly lower in
adipose tissue of obese patients than in that of nonobese
patients and to be negatively correlated with BMI, waist
circumference, and insulin levels, consistent with the
hypothesis that the expression and activation of PRKAR2B
might contribute to the different lipolytic response to
b-adrenergic activation in obesity (12). In the light of the
results of the present study, demonstrating the effects
of PRKAR2B silencing in cultured cells, it appears that
further studies are needed to investigate the role of
PRKAR2B in adipogenesis in vivo and to determine
whether a decrease in lipolysis would be sufficient tohttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0049
 2013 The authors
Published by Bioscientifica Ltdexplain obesity and the possible relative involvement of
adipogenesis.
This is the first study, to our knowledge, to investigate
the expression and role of PKA regulatory subunits in an
experimental cell model of adipogenesis. In this model, we
found that PRKAR2B was the key regulatory subunit in
both murine and human preadipocytes during adipogen-
esis. The increase in the expression of PRKAR2B during the
first few days of adipocyte differentiation in vitro might
per se suggest a role for this regulatory protein in the pro-
gression of adipogenesis. This hypothesis was confirmed
by transient transfection with siRNA against PRKAR2B of
both immortalized 3T3-L1 murine cells, one of the most
frequently used preadipocyte lines, and primary human
preadipocytes, which better reflects adipose tissue biology
in vivo. Data obtained from both the experimental models
showed that the silencing of PRKAR2B resulted in the
expected abolishment of the increase in the expression of
PRKAR2B during adipogenesis that was associated with an
impaired lipid accumulation in differentiating adipocytes.This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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11–12 2 :206Adipogenesis involves a cascade of transcription
factors, among which PPARg and C/EBPs are considered
to be the crucial determinants of adipocyte fate. However,
despite the importance of C/EBPs in adipogenesis, these
transcription factors cannot function efficiently in the
absence of PPARg. PPARg, the master regulator of
adipogenesis, belongs to the nuclear receptor superfamily
of ligand-activated transcription factors and is both
necessary and sufficient for adipogenesis (26). In fact,
most pro-adipogenic factors seem to function, at least
in part, by activating the expression and/or activity of
PPARg and, to date, no factor that can rescue adipogenesis
in the absence of PPARg has been identified. The
endogenous PPARg ligand is unknown; however, it has
recently been demonstrated that increases in cAMP levels
result in the transient production of a biologically relevant
PPARg ligand in 3T3-L1 cells during adipogenesis (27).
Moreover, the activation of CREB promotes the expression
of PPARg (6). In the present study, we found that the
expression of PPARg did not increase in the absence of the
physiological rise in the expression of PRKAR2B during
adipocyte differentiation in both murine and human cell
models. In turn, this event led to the abolishment of lipid
accumulation in adipocyte progenitors, although stimu-
lated to differentiate. Moreover, the expression of LPL,
a protein associated with terminal differentiation of
adipocytes, was also impaired by blocking the expression
of PRKAR2B. This observation is consistent with results
from previous studies demonstrating that embryonic stem
cells lacking PPARg do not contribute to fat formation
(28, 29) and that the abolishment of the expression of
PPARg at the adipose tissue level prevents WAT develop-
ment (30, 31, 32). In accordance with this, humans with
dominant-negative PPARg mutations display abnormal
body fat distribution, demonstrating a crucial role for
PPARg also in human adipose tissue development (33, 34).
In the models used in the present study, in which the
expression of PPARg was not selectively abolished, we
found that the silencing of PRKAR2B significantly
interfered with the normal expression of PPARg and LPL.
Although the pathway by which intracellular cAMP may
influence the expression of PPARg is still unclear, we
are tempted to speculate that PKA holoenzyme may be
involved in cAMP-mediated PPARg induction.
In conclusion, the present study shows that PRKAR2B
is the key PKA regulatory subunit in mouse and human
adipose tissue development. PRKAR2B is the main
regulatory subunit expressed in human adipose tissue
during fetal development and the increase in itshttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0049
 2013 The authors
Published by Bioscientifica Ltdexpression during murine and human adipocyte differen-
tiation seems to be an essential event in adipogenesis.Declaration of interest
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